How should orthostatic hypotension be diagnosed and managed?

Orthostatic Hypotension: Diagnosis and Management

Diagnose orthostatic hypotension by measuring blood pressure after 5 minutes supine and again at 3 minutes standing—a drop of ≥20 mmHg systolic or ≥10 mmHg diastolic confirms the diagnosis 1, 2.

Diagnostic Approach

Blood Pressure Measurement Protocol

Perform the simplified Schellong test at bedside 2:

• Measure BP and heart rate after 5 minutes supine
• Have patient stand and measure again at 3 minutes
• Critical timing note: Measuring only after seated position or delaying standing measurements beyond 3 minutes will miss clinically relevant cases 3

Subtypes to Recognize

The guideline defines four distinct patterns 1:

• Initial OH: BP drop within 15 seconds of standing (transient, causes presyncope/syncope)
• Classic OH: Sustained drop within 3 minutes
• Delayed OH: Drop occurring after >3 minutes (may require ≥30 mmHg systolic drop if supine hypertension present)
• Neurogenic OH: Due to autonomic dysfunction, not environmental triggers

Key Diagnostic Distinction

Determine if OH is neurogenic versus non-neurogenic 4—this fundamentally changes prognosis and management:

• Neurogenic: Inadequate heart rate response to BP drop, often earliest sign of Parkinson's disease or synucleinopathies, frequently coexists with supine hypertension
• Non-neurogenic: Appropriate compensatory tachycardia, typically due to medications, dehydration, or blood loss

If bedside testing is negative but clinical suspicion remains high, or if patient cannot stand safely, proceed to head-up tilt table testing at 60 degrees 2.

Management Algorithm

Step 1: Address Underlying Causes

• Review and remove aggravating medications 5—this is the foundation, not just antihypertensives but any culprit drugs
• Correct volume depletion, anemia, or metabolic abnormalities
• Treat diabetes mellitus aggressively (major risk factor across all ages) 2

Step 2: Non-Pharmacological Interventions (Primary Treatment)

These are the cornerstone of management 4, 6:

Dietary modifications:

• Increase fluid intake to 2-3 liters daily
• Increase salt intake (unless contraindicated)
• Avoid large meals; eat smaller, frequent meals
• Avoid alcohol

Physical counterpressure maneuvers 4:

• Leg crossing while standing
• Squatting
• Muscle tensing of legs, abdomen, and buttocks
• These acutely raise BP when symptoms occur

Compression garments:

• Abdominal binders (more effective than leg compression alone)
• Waist-high compression stockings (30-40 mmHg)

Positional strategies:

• Elevate head of bed 10-20 degrees at night (reduces supine hypertension and nocturnal diuresis)
• Rise slowly from supine to sitting to standing
• Avoid prolonged standing and hot environments

Step 3: Pharmacological Treatment (When Non-Pharmacological Measures Insufficient)

First-line agents 2, 6:

• Midodrine: Alpha-1 agonist, short-acting (take during daytime only to avoid supine hypertension)
• Droxidopa: Synthetic norepinephrine precursor, particularly for neurogenic OH

Second-line:

• Fludrocortisone: Improves symptoms but has concerning long-term effects (fluid retention, hypokalemia, supine hypertension) 2—use cautiously

Combination therapy: May be necessary for severe cases 6—individualize based on 24-hour BP profile and severity

Critical Management Pitfall: Concomitant Supine Hypertension

This is the most challenging scenario, occurring frequently with neurogenic OH 7, 5:

• Do NOT simply de-prescribe antihypertensives—this worsens supine/seated hypertension, which drives adverse cardiovascular events
• Instead:
  • Optimize antihypertensive timing (give at bedtime to target nocturnal hypertension)
  • Use short-acting pressor agents (midodrine) only during daytime
  • Elevate head of bed at night
  • Accept slightly higher standing BP targets to avoid dangerous supine hypertension

Recent evidence shows intensive BP control may actually reduce OH risk 3, 5—the traditional approach of stopping antihypertensives is often counterproductive.

Prognostic Implications

OH significantly increases mortality and morbidity 2, 7:

• Up to 50% increase in all-cause mortality
• Increased risk of falls, fractures, dementia, cardiovascular disease, and stroke
• Neurogenic OH has worse prognosis, often heralding neurodegenerative disease 4

Therefore, aggressive treatment is warranted even when asymptomatic 4—the condition increases adverse outcomes regardless of symptoms.